Solid IO

Solid IO, founded in 2025 and headquartered in Finland, is pioneering advancements in precision oncology and immunotherapy through its unique organ-on-chip technology. The company's slogan, "ENDING THE GUESSWORK IN CANCER CARE," underscores its commitment to providing patient-specific data that empowers stakeholders in the cancer care ecosystem.

By replicating the tumor microenvironment, Solid IO enables real-time insights that can transform drug development, clinical trials, and therapy access for cancer patients worldwide. Their platform is engineered to optimize drug development and improve patient outcomes by predicting treatment responses efficiently.

The recent spinout investment of €800.00K, led by BSV Ventures and Nordic Science Investments in February 2025, highlights significant investor confidence in Solid IO's disruptive potential. The company is actively seeking visionary partners to further its global expansion and make precision oncology more accessible and clinically relevant. With collaborations already spanning cancer clinics, research centers, and pharmaceutical companies, Solid IO is at the forefront of redefining cancer care on a global scale.